八珍汤联合大剂量化疗治疗骨肉瘤临床观察  

Clinical Observation of Bazhen Decoction Combined with High-Dose Chemotherapy on Osteosarcoma

作　　者：陈婧[1] 刘云霞[1] 匡唐洪[1] 姚勇伟[1] 

机构地区：[1]杭州市第三人民医院肿瘤科,浙江杭州310009

出　　处：《中华中医药学刊》2015年第4期940-943,共4页Chinese Archives of Traditional Chinese Medicine

基　　金：浙江省中医药管理局基金项目(2012ZB131)

摘　　要：目的:评价八珍汤对骨肉瘤患者化疗后的临床疗效。方法:64例骨肉瘤患者随机分为治疗组及对照组,各32例。化疗前后观察八珍汤干预围化疗期患者:(1)外周血象及CD4+/CD8+;(2)升白细胞及升血小板药物的用量;(3)生存质量评分;(4)总生存率和无病生存率。结果:两组化疗后Kf评分、CD4+/CD8+均有明显的下降(P<0.05),八珍汤能降低化疗后患者的Kf积分及CD4+/CD8+下降的幅度(P<0.05);减少化疗过程中升白细胞及升血小板药物的使用量(P<0.05);两组治疗后的总生存率和无病生存率无明显差异(P>0.05)。结论:八珍汤可以减少化疗对骨髓的抑制作用,改善化疗患者的生存质量。Objective： To evaluate the clinical efficacy of Bazhen Decoction on osteosarcoma after chemotherapy. Method：64 patients were divided into treatment group and control group,32 patients in each group. Before and after chemotherapy,the intervention of Bazhen Decoction was observed,including peripheral blood and CD4^＋/ CD8^＋,the dosage of leukocyte and blood platelet increasing agent,life quality score,overall survival and disease-free survival. Result： Two groups＇ Kf score and CD4^＋/ CD8^＋were significantly decreased（ P〈0. 05） after chemotherapy. The prescription can reduce Kf points and CD4^＋/ CD8^＋（ P〈0. 05） and can reduce the dosage of leukocyte and blood platelet increasing agent（ P〈0. 05）. The overall survival and disease-free survival of two groups had no obvious difference（ P〉0. 05）. Conclusion：Bazhen Decoction can reduce the inhibitory effect of chemotherapy on bone marrow and improve the patients＇ quality of1 ife.

关 键 词：八珍汤 骨肉瘤 化疗 临床观察 

分 类 号：R273[医药卫生—中西医结合]